California Dreaming: Long-Term Messages From Governor’s Rx Price Actions
Executive Summary
Immediate impact of California Governor Newsom’s directive on drug pricing unlikely to be dramatic, but there are important long-term messages for biopharma companies to weigh.
You may also be interested in...
Outcomes-Based Contracts May Be Negotiated By Michigan Medicaid
Michigan follows Oklahoma in gaining approval to negotiate supplemental rebates in the context of value-based contracts for drugs. Oklahoma now has four novel contracts in place.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.